Alterity obtains authorisation in Italy for Phase II trial of multiple system atrophy therapy
The randomised, double-blind, placebo-controlled trial will analyse ATH434 in early-stage MSA patients.

The randomised, double-blind, placebo-controlled trial will analyse ATH434 in early-stage MSA patients.
The Curebase platform will used by researchers to obtain data that will be assessed to determine progress in senior individuals.
The vaccine was well-tolerated and its tolerability was better at the second dose with no serious adverse events reported.
The Italian cohort enrolled ten subjects who received narsoplimab under compassionate use at ASST Papa Giovanni XXIII Hospital.
Biotech firm ReiThera has reported that the preliminary results from the ongoing Phase I study showed that its Covid-19 vaccine…
Italy has started human trials of a potential Covid-19 vaccine as part of the global efforts to develop a response…
FibroGen recently announced enrolment of patients in a clinical study of its antibody drug pamrevlumab as a potential Covid-19 treatment
ByFibroGen has started patient enrolment for a Phase II/III clinical trial of pamrevlumab for the treatment of severe Covid-19 infection…
Thank you for subscribing to Clinical Trials Arena